Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | VCP | P55072 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12612817 | 0.89 | ROCK2 (0.55) | ROCK2SYKEGFRKDRMAPKAPK2 | |
| SCHEMBL849257 | 0.85 | SYK (0.62) | ROCK2SYKEGFRKDRCDK1 | |
| SCHEMBL14045610 | 0.84 | ROCK2 (0.52) | ROCK2SYKEGFRKDRVCP | |
| SCHEMBL14024356 | 0.84 | KDR (0.66) | ROCK2SYKEGFRKDRCDK1 | |
| SCHEMBL12520447 | 0.82 | DOT1L (0.52) | ROCK2SYKEGFRKDRVCP | |
| SCHEMBL4875875 | 0.81 | IGF1R (0.58) | SYKEGFRKDRMAOAMAOB | |
| SCHEMBL12696433 | 0.81 | KDR (0.42) | ROCK2SYKKDRVCPMAPKAPK2 | |
| SCHEMBL14548801 | 0.81 | ROCK2 (0.49) | ROCK2SYKEGFRKDRVCP | |
| SCHEMBL6979822 | 0.80 | SYK (0.41) | ROCK2SYKEGFRKDRMAPKAPK2 | |
| SCHEMBL4879974 | 0.80 | AURKA (0.62) | SYKKDRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688883-B1 | PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2688883-B1 | PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-9006241-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-9006241-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| US-8901143-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-8901143-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| EP-2502924-A1 | Novel pyrimidine derivatives | Chemilia AB (SE) | 2012-09-26 | — | — | EP | disclosed |
| EP-2433636-A1 | Treatment of Malignant Diseases | Medizinische Universität Wien (AT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011144742-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011144742-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2011-11-24 | — | — | WO | disclosed |
| EP-2154967-A1 | PYRIMIDINE DERIVATIVES | Hutchison Medipharma Enterprises Limited (BS) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008128231-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008128231-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | ROCK2 723/4885SYK 2248/4885EGFR 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.